[go: up one dir, main page]

PE20141945A1 - Derivados de quinolina como inhibidores de la enzima pde10a - Google Patents

Derivados de quinolina como inhibidores de la enzima pde10a

Info

Publication number
PE20141945A1
PE20141945A1 PE2014000989A PE2014000989A PE20141945A1 PE 20141945 A1 PE20141945 A1 PE 20141945A1 PE 2014000989 A PE2014000989 A PE 2014000989A PE 2014000989 A PE2014000989 A PE 2014000989A PE 20141945 A1 PE20141945 A1 PE 20141945A1
Authority
PE
Peru
Prior art keywords
inhibitors
quinoline
pde10a enzyme
quinoline derivatives
compounds
Prior art date
Application number
PE2014000989A
Other languages
English (en)
Inventor
Jan Kehler
Jacob Nielsen
Ask Puschl
John Paul Kilburn
Morten Langgard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48667762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20141945A1 publication Critical patent/PE20141945A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINOLINA DE FORMULA (I) DONDE R1, R2, R3, R4, R5 Y R6 SON CADA UNO H, HIDROXILO, CN, ALCOXI(C1-C6), ENTRE OTROS; L ES UN CONECTOR TAL COMO -CH2-CH2- O -CH=CH-; HET ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: 2-[(E)-2-(5,8-DIMETIL-[1,2,4]TRIAZOLO[1,5-a]PIRAZIN-2-IL)-VINIL]-6-TRIFLUOROMETIL-QUINOLINA; 6-[2-(5,8-DIMETIL-[1,2,4]TRIAZOLO[1,5-a]PIRAZIN-2-IL)-ETIL]-1,3-DIOXOLO[4,5-g]QUINOLINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA PDE10A SIENDO UTILES EN EL TRATAMIENTO DE TRANSTORNOS PSIQUIATRICOS O NEURODEGENERATIVOS
PE2014000989A 2011-12-21 2012-12-21 Derivados de quinolina como inhibidores de la enzima pde10a PE20141945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201100990 2011-12-21

Publications (1)

Publication Number Publication Date
PE20141945A1 true PE20141945A1 (es) 2014-12-18

Family

ID=48667762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000989A PE20141945A1 (es) 2011-12-21 2012-12-21 Derivados de quinolina como inhibidores de la enzima pde10a

Country Status (32)

Country Link
US (2) US9216986B1 (es)
EP (1) EP2794606A1 (es)
JP (1) JP6073918B2 (es)
KR (1) KR20140105574A (es)
CN (1) CN104114554A (es)
AP (1) AP2014007697A0 (es)
AR (1) AR089361A1 (es)
AU (1) AU2012356885B2 (es)
BR (1) BR112014015192A2 (es)
CA (1) CA2859702A1 (es)
CL (1) CL2014001643A1 (es)
CO (1) CO6990727A2 (es)
CR (1) CR20140289A (es)
DO (1) DOP2014000141A (es)
EA (1) EA028824B1 (es)
EC (1) ECSP14010000A (es)
GE (1) GEP201706657B (es)
HK (1) HK1202861A1 (es)
IL (1) IL233226A (es)
MA (1) MA35860B1 (es)
MD (1) MD20140070A2 (es)
MX (1) MX348792B (es)
MY (1) MY165216A (es)
PE (1) PE20141945A1 (es)
PH (1) PH12014501434B1 (es)
RU (1) RU2624440C2 (es)
SG (1) SG11201403339YA (es)
TN (1) TN2014000268A1 (es)
TW (1) TWI570124B (es)
UA (1) UA111871C2 (es)
WO (1) WO2013092974A1 (es)
ZA (1) ZA201404533B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI570124B (zh) 2011-12-21 2017-02-11 H 朗德貝克公司 作為pde10a酵素抑制劑的喹啉衍生物
CN108690053A (zh) * 2012-11-29 2018-10-23 桑诺维恩药品公司 杂芳基化合物和其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
DE602004028827D1 (de) 2003-06-30 2010-10-07 Nycomed Gmbh Pyrrolodihydroisochinoline als pde10- inhibitoren
EP1641457B1 (en) 2003-06-30 2009-08-05 Nycomed GmbH Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005082883A2 (en) 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
MXPA06014236A (es) 2004-06-07 2007-02-14 Pfizer Prod Inc Inhibicion de la fosfodiesterasa 10 como tratamiento para las afecciones relacionadas con el sindrome metabolico y con la obesidad.
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
RU2479576C9 (ru) 2008-05-14 2014-03-10 Астеллас Фарма Инк. Амидное соединение
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為pde10a酵素抑制劑的2-芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのpde10阻害薬としての使用
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
TWI570124B (zh) 2011-12-21 2017-02-11 H 朗德貝克公司 作為pde10a酵素抑制劑的喹啉衍生物

Also Published As

Publication number Publication date
RU2624440C2 (ru) 2017-07-04
MX2014007409A (es) 2014-08-01
JP6073918B2 (ja) 2017-02-01
UA111871C2 (uk) 2016-06-24
CR20140289A (es) 2014-08-18
WO2013092974A1 (en) 2013-06-27
RU2014127984A (ru) 2016-02-10
MX348792B (es) 2017-06-29
MY165216A (en) 2018-03-09
HK1202861A1 (en) 2015-10-09
BR112014015192A8 (pt) 2017-06-13
GEP201706657B (en) 2017-04-25
CO6990727A2 (es) 2014-07-10
CL2014001643A1 (es) 2014-11-21
EA028824B1 (ru) 2018-01-31
NZ626279A (en) 2015-07-31
SG11201403339YA (en) 2014-07-30
IL233226A0 (en) 2014-08-31
US9216986B1 (en) 2015-12-22
IL233226A (en) 2017-11-30
AP2014007697A0 (en) 2014-06-30
PH12014501434A1 (en) 2014-09-22
KR20140105574A (ko) 2014-09-01
ZA201404533B (en) 2015-12-23
AU2012356885A1 (en) 2014-07-10
US20160303120A1 (en) 2016-10-20
ECSP14010000A (es) 2015-12-31
MA35860B1 (fr) 2014-12-01
DOP2014000141A (es) 2014-07-31
EA201491152A1 (ru) 2015-01-30
MD20140070A2 (ro) 2014-12-31
PH12014501434B1 (en) 2014-09-22
TW201339156A (zh) 2013-10-01
US9801878B2 (en) 2017-10-31
EP2794606A1 (en) 2014-10-29
TN2014000268A1 (en) 2015-09-30
BR112014015192A2 (pt) 2017-06-13
US20150376186A1 (en) 2015-12-31
CN104114554A (zh) 2014-10-22
JP2015502970A (ja) 2015-01-29
CA2859702A1 (en) 2013-06-27
TWI570124B (zh) 2017-02-11
AR089361A1 (es) 2014-08-20
AU2012356885B2 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
MD20140130A2 (ro) 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
MX381326B (es) Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
PH12014501695A1 (en) Pde9 inhibitors with imidazo triazinone backbone
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
PE20161552A1 (es) Compuestos de dihidroisoquinolinona sustituida
EP2288260A4 (en) TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20071104A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv (dpp-4)
UA107952C2 (uk) ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20130346A1 (es) Compuestos heterociclicos fusionados
NZ600430A (en) Spiro-oxindole mdm2 antagonists
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
NZ626394A (en) Substituted annulated pyrimidines and triazines, and use thereof
MX336271B (es) Compuestos de triazolopiridina inhibidores de jak y los metodos.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
PE20141351A1 (es) Triazolopiridinas
PE20142244A1 (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CL2011001152A1 (es) Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed